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Background: Thalidomide was introduced in the 1950s as a nontoxic sedative, but was removed from the market 
because of its teratogenicity. Recent studies have demonstrated that the most likely etiology of limb defects produced 
by fetal exposure to thalidomide is the inhibition of angiogenesis in the developing limb bud. Also many studies 
have shown that thalidomide inhibits tumor growth in several malignancies by the inhibition of VEGF. Methods: 
We determined whether the systemic administration of thalidomide inhibits colon cancer liver metastasis in mice. 
We also evaluated the optimal schedule of this treatment against murine colon cancer liver metastasis. Murine 
colon cancer CT-26 cells were implanted into the spleens of BALB/c mice. 7 days after tumor implantation, the mice 
received an intra-peritoneal injection of thalidomide (0, 30 mg/kg) daily or every other day (3 times per week). 
After the treatments, all mice were sacrificed. The numbers of liver metastases were counted and the expression of 
VEGF and the micro vessel density were analyzed by immunohistochemistry against liver metastases. Results: 4 
out of 10 mice which received a daily administration of thalidomide (30 mg/kg) died. But in this group, we found a 
significant reduction in the number of liver metastases compared with the control group (0 mg/kg). All mice which 
received thalidomide every other day survived. In this group, there was also a significant reduction in the number 
of liver metastases compared with the control. Immunohistochemical analysis revealed lower expressions of VEGF 
and CD31 in the liver metastases of mice which received thalidomide every other day compared with the control. 
Conclusion: The systemic administration of thalidomide inhibits liver metastasis of colon cancer in mice by the 
downregulation of VEGF and angiogenesis. The every other day administration of thalidomide was the optimal 
schedule in this model. 
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Introduction
　Colorectal cancer is the four th most common 
malignancy and the second leading cause of cancer 
death in the United States. Despite the considerable 
energy spent on cancer research and the introduction of 
new therapies, the prognosis for colorectal cancer is still 
poor, with a mean overall 5 year survival rate of around 
50 %1). The major cause of death from colorectal cancer 
is liver metastasis resistant to conventional therapy 2). 
Metastasis depends on the induction of an adequate 
and new blood supply, i.e., angiogenesis3). Vascular 
endothelial growth factor (VEGF) is one stimulator of 
angiogenesis and its expression correlates with tumor 
vasculature and colon cancer liver metastasis4).
　Thalidomide was introduced in the 1950s as a 
nontoxic sedative, but was removed from the market 
because of its teratogenicity. Recent studies have 
demonstrated that the most likely etiology of limb 
defects produced by fetal exposure to thalidomide is the 
inhibition of angiogenesis in the developing limb bud5). 
Thalidomide has been shown to inhibit VEGF and basic 
fibroblast growth factor (bFGF)-induced angiogenesis6). 
This anti-tumor ef fect of thalidomide has also been 
reported in several clinical trials7-10). In colorectal cancer, 
combination therapy with paclitaxel and thalidomide 
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inhibits the angiogenesis and growth of human colon 
cancer xenografts in mice11). Good response rates 
were also demonstrated in a combination therapy with 
irinotecan and thalidomide against colorectal cancer in 
a phase II trial12). However we have not yet elucidated 
the optimal schedule of treatment against colorectal 
cancer for thalidomide. 
　In the present study, we investigated that the efficacy 
of intra peritoneal injections of thalidomide inhibited 
liver metastasis in syngeneic mice. 
Materials and methods
Thalidomide. Thalidomide was obtained from Tocris 
Cookson Inc. Its chemical structure has been published 
previously 13-16). Dimethyl sulfoxide (DMSO) soluble 
thalidomide to 25 mM. 
Reagents. Eagle’s minimum essential  medium 
(EMEM), Ca2＋- and Mg2＋- free Hanks’ balanced solution 
(HBSS), and fetal bovine serum (FBS) were purchased 
from M.A.Bioproducts (Walkersville,MD). 
Cells and cell culture. CT-26 murine colon carcinoma 
cells syngeneic to BALB/c mice were grown as mono-
layers in MEM supplemented with 5 % FBS, vitamins, 
sodium pyruvate, L-glutamine, and non-essential 
amino acids. All cultures were free of mycoplasma, 
the reovirus, type3 pneumonia virus of mice, K virus, 
ectomelia virus, and lactate dehydrogenase virus. 
CT-26 cells produce a high expression of murine VEGF 
protein and this expression is associated with colon 
cancer liver metastasis17).
Experimental Liver metastasis. Specific pathogen-
free male BALB/c mice were purchased from Saitama 
Experimental Animals Supply Corporation. Animals 
were maintained according to institutional guidelines 
for facilities approved by the Japanese Association of 
Laboratory Animal Care. The mice were used according 
to institutional guidelines when they were 10 weeks old.
　CT-26 colon cancer cells in the exponential growth 
phase were harvested by a brief exposure to a 0.25 % 
trypsin –0.1 % EDTA solution. The cell suspensions 
were pipetted to produce single-cell suspensions, 
washed, and resuspended in HBSS. Cell viability was 
determined by trypan blue exclusion, and only single-
cell suspensions with a viability of greater than 90 % 
were used. Mice were anesthetized by intraperitoneal 
injections of Nembutal (30 mg/kg) and placed in the 
supine position. A midline abdominal incision was made 
and the spleen was exteriorized. The incision was closed 
in one layer with wound clips18). Tumor cells (5×103/
mouse) were injected into the spleen, and at the end 
of the study, the mice were sacrificed. The livers were 
removed and placed in Bouin’s solution. The number of 
experimental liver metastases was determined with the 
aid of a dissecting microscope, and the number of liver 
lesions smaller than 1mm in diameter was determined 
in representative sections stained with H and E using a 
light microscope.
Systemic therapy with thalidomide. On day 7 after 
the inoculation, the mice received an intra-peritoneal 
injection of thalidomide (0, 30 mg/kg) daily or every 
other daily (3 times per week). On day 21 after the 
inoculation, all mice were sacrificed. The number of 
liver metastases was counted and the expression of 
VEGF and the micro vessel density were analyzed by 
immunohistochemistry against liver metastases.
Histology and immunohistochemstry. Livers that 
contained colon cancer metastases were divided into 
fragments and placed in either 10 % neutral formalin 
(vol/vol) or OCT compound (Miles laboratories, 
Elkhar t, IN) to be snap-frozen in liquid nitrogen. 
For histological study, consecutive 5-μm sections 
were stained with H&E. For immunohistochemical 
analysis, frozen sections (10μm) were fixed with cold 
acetone. Tissue sections (5μm) of formalin-fixed, 
paraffin-embedded specimens were treated in xylene, 
rehydrated in a graded alcohol series, and transferred 
to PBS for 12 min. Non-specific reactions were blocked 
by incubating the section with a solution containing 5 
% normal serum and 1 % normal goat serum for 20 min 
at room temperature. Excess blocking solution was 
drained, and the slides were incubated overnight at 4℃
with antibodies to CD31 (1:400 dilution; Pharmingen, 
San Diego, CA), and VEGF (1:20 dilution; Oncogene, 
Cambridge, MA). They were then rinsed three times 
with PBS and incubated with peroxidase-conjugated 
secondary antibody for 60 min at room temperature, 
followed by rinsing with PBS and incubation with 
diaminobenzamine (Research Genetics, Huntsville, AL) 
for 5 min. The sections were counter-stained with Gill’s 
hematoxylin. A positive reaction in this assay stained 
reddish brown due to a precipitate in the cytoplasm. The 
intensity of staining was quantified in three different 
areas of each sample by an image analyzer using the 
Optimas software program (Bioscan, Edmonds, WA) 
to yield an average measurement19). Endothelial cells 
(CD31＋) in ten ‘ hot spots’ 20) of the liver tumors were 
counted under ×100 magnification microscopic fields 
(×10 objective and ×10 ocular, 0.14mm2 per field) and 
expressed as the number per mm2  21). Based on criteria 
for microvessel density described by Weidner et al 22), 
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it was not necessary to observe the vessel lumen to 
classify the structure as a vessel. We designed negative 
control for immunohistochemical analysis by without 
secondary antibodies in these studies.
Statistical Analysis. Significant dif ferences in 
the data were analyzed by the Mann-Whitney U test. 
P-values ＜0.05 were considered significant.
Results
CT-26 colon cancer liver metastasis with the 
systemic administration of thalidomide. We 
examined whether the systemic administration of 
thalidomide inhibits the number of experimental 
liver metastases. Viable 5× 103 CT-26 cells were 
implanted into the spleens of mice. 7 days after tumor 
implantation, mice received an intra-peritoneal injection 
of thalidomide (0, 30 mg/kg) daily or every other day 
(3 times per week). The number of liver metastases 
was counted. 4 out of 10 mice which received a daily 
administration of thalidomide (30 mg/kg) died in 
this study. But in this group, we found a significant 
inhibition of the number of liver metastases compared 
with the control group (0 mg/kg) (Table 1). 
　All mice which received thalidomide every other 
day survived. In this group, there was a significant 
inhibition of the number of liver metastases compared 
with the control group (Table 1).
Microvessel density and the expression of VEGF in 
hepatic metastases with thalidomide. To determine 
whether thalidomide inhibits the tumor vasculatures 
of  l iver metastases,  we examined microvessel 
density and the expression of murine VEGF by 
immunohistochemical analysis using antibodies against 
the endothelial cell marker CD31 and murine VEGF. 
Liver metastases exposed to a daily administration of 
thalidomide were significantly inhibited with regard to 
the formation of new blood vessels (Fig. 1). Also the 
average microvessel density of lesions which received 
thalidomide every other day was inhibited (225±80 
vessels/mm2 compared with 327±70 vessels/mm2 in 
the control tumors) (mean±SEM) (Fig. 1, 2).  
Table 1. Murine colon cancer liver metastasis with thalidomide
CT26 cells were inoculated into the spleens of mice. On day 
7 after the inoculation, the mice received an intra-peritoneal 
injection of thalidomide (0, 30 mg/kg) daily or every other 
daily (3 times per week). The number of liver metastases was 
counted.  4 out of 10 mice which received a daily administration 
of thalidomide (30 mg/kg) died on day 4 after treatment. We 
stopped this experiment on day 16. All mice which received 
thalidomide every other day survived in this study. All mice 
were sacriﬁced  on day 21. *P<0.05 compared with the control 
(0 mg/kg).
　Treatment  　　　 Liver metastasis
   Incidence  Meta. No
    　　　　Median (range)
Thalidomide (every day) 
　0 mg/kg  10/10    5　(1-37) 
　30 mg/kg    5/6    4　(0 -4)*
Thalidomide (every other day) 
　0 mg/kg    9/10  13　(0 -50) 
　30 mg/kg    8/10    4　(0 -31)*
Fig. 1. Tumor vasculature of CT26 liver metastasis with 
thalidomide. CT26 murine colon cancer cells were injected 
into the spleens of mice on day 0. On day 7, the mice received 
a systemic administration of thalidomide (0, 30 mg/kg) 
daily or every other day (3 times per week). After treatment, 
all mice were sacrificed and the hepatic metastases were 
processed for the immunohistochemistry against the CD31 
antibody. Tumor vasculature reductions were observed in 
liver tumors with thalidomide.
Fig. 2. MVD of hepatic metastasis with thalidomide. 
Endothelial cells (CD-31＋) in liver tumors were counted under 
x100 magnification microscopic fields and expressed as the 
number of cells per mm2. The average microvessel density 
(MVD) of the lesions which received thalidomide every other 
day was inhibited signiﬁcantly (p＜0.05 vs control).
0mg/kg 30mg/kg (every other day)
*p<0.05 vs control
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Also, the inhibition of VEGF protein expression 
correlated with a reduction in the tumor vasculature 
of hepatic lesions with the systemic administration of 
thalidomide (Fig. 3). In the normal hepatic areas, we 
found a lower expression of VEGF and CD31 compared 
with liver metastases.
Discussion
　Our results demonstrated that the systemic 
administration of thalidomide to syngeneic mice 
with liver metastasis of murine colon cancer inhibits 
angiogenesis associated with the inhibition of VEGF 
expression. Altering the time schedule of administration 
influenced the therapeutic outcome.
　The progressive growth of primar y neoplasms 
and metastases depends on angiogenesis3, 23, 24), and 
the extent of angiogenesis is determined by the 
balance between proangiogenic and antiangiogenic 
molecules15-17). Angiogenesis induced by colon cancer 
is associated with VEGF, bFGF, IL-8, and MMP-9 4, 25-29). 
The expression of VEGF cor relates with tumor 
vasculature and colon cancer liver metastasis4). 
　Thalidomide was first marketed as a sedative 
hypnotic in 1957. It was withdrawn from the market 
in 1961 as it was found to cause congenital defects30). 
Thalidomide has been shown to inhibit VEGF, basic 
fibroblast growth factor (bFGF) and interleukin-8 (IL-
8)-induced angiogenesis5, 6, 31). This anti-tumor effect has 
also been reported in several clinical trials7-10). 
　Previous studies have shown that the major toxicity of 
thalidomide is a reversible sedative. Additional serious 
toxicities include peripheral neuropathy, thrombosis, 
and a rash32-35). Thyroid dysfunction has also been 
reported36). In a clinical trial of thalidomide in patients 
with Kaposi’s sarcoma, the maximum tolerated dose 
(MTD) was 600 mg/day, with dose-limiting toxicity 
(DLT) of somnolence and a rash37).
　In this study, 4 out of 10 mice which received a daily 
administration of thalidomide (30 mg/kg) died on day 
4 after treatment. In our preliminary studies, all mice 
which received a daily administration of thalidomide 
(300 mg/kg) died on day 4 after treatment (data not 
shown).We suggest that the cause of death was the 
suppression of breathing due to somnolence in mice. 
All mice which received thalidomide ever y other 
day survived in this study. In preliminary studies, we 
administered thalidomide (3 mg/kg) every other day. 
There were no significant inhibitions of liver metastasis 
and the expression of VEGF compared with the control 
(data not shown). 
In our study intra peritoneal administration was 
employed as previously described 38). Kotoh et al.39) 
repor ted the antiangiogenic ef fect of thalidomide 
on human esophageal cancer in nude mice by 
intraperitoneal administration. Whereas same effect 
were not observed when mice were treated by gavage 
administration. In clinics, thalidomide is used by oral 
administration. However, single-agent thalidomide is 
generally well-tolerated drug that showed no antitumor 
activity in patients with advanced metastatic colorectal 
cancer40). The mechanisms underlying the strong effect 
of antiangiogenesis by intraperitoneal root but poor 
efficiency by oral route remain unclear, the reasons 
might be the bioavailability of the active form of 
thalidomide at tumor site. 
In summary, an every other day administration of 
thalidomide (30 mg/kg) is optimal schedule for this 
model. This schedule produced the highest ef ficacy 
against colon cancer liver metastasis and its therapeutic 
ef fect was correlated with the reduction of tumor 
vasculature in mice. To improve the prognosis and 
safety of clinical trials of thalidomide against colon 
cancer liver metastasis, we need to develop an optimal 
dose and schedule in the future.
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